The fact that TGOLN2 expression was recently shown to correlate with irinotecan sensitivity in CRC [72] and cisplatin resistance in lung adenocarcinioma [73] supports this idea and confirms the reliability of CancerHubs predictions. The gene discussed is TGOLN2; the disease is colorectal carcinoma.